RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
Mayuri CharnaliaSupriya ChopraJaahid MulaniPalak PopatSushmita RathMaarten ThomeerPrachi MittalAnkita GuptaIngrid A BoereSudeep GuptaRemi A NoutPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
The study showed 1.5% and 3% difference in disease-free survival at 18 and 24 months and no difference in progression-free survival between RECIST 1.1 and standard evaluation in a patient cohort with low event rate.
Keyphrases